In utero gene therapy: Prospect and future

Current Pharmaceutical Design

Volumn 10, Issue 29, 2004, Pages 3663-3672

  Chauhan, D P ^a   Srivastava, A S ^a   Moustafa, M E ^a   Shenouda, S ^a   Carrier, E ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Fetus; Gene therapy; In utero; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ALPHA GLOBIN; ALPHA MANNOSIDASE; BETA GLUCURONIDASE; BETA N ACETYLHEXOSAMINIDASE; CEREBROSIDE SULFATASE; DYSTROPHIN; FUMARYLACETOACETASE; GENE PRODUCT; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSYLCERAMIDASE; GLUCURONOSYLTRANSFERASE; IDURONATE 2 SULFATASE; KALININ; LEVO IDURONIDASE; NEUROTROPHIN 3; ORNITHINE CARBAMOYLTRANSFERASE; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; SURVIVAL MOTOR NEURON PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALPHA THALASSEMIA; CATTLE; CELL DIVISION; CLINICAL PROTOCOL; COMPETENCE; CRIGLER NAJJAR SYNDROME; CYSTIC FIBROSIS; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; EPIDERMOLYSIS BULLOSA; EXPERIMENTAL MODEL; FEASIBILITY STUDY; FETUS CELL; FETUS DEVELOPMENT; GAUCHER DISEASE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC ENGINEERING; GLYCOGEN STORAGE DISEASE TYPE 2; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUNTER SYNDROME; HURLER SYNDROME; IMMUNE RESPONSE; IMMUNE SYSTEM; MANNOSIDOSIS; MEDICAL ETHICS; MEDICAL RESEARCH; METACHROMATIC LEUKODYSTROPHY; METHODOLOGY; MORBIDITY; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; PRENATAL PERIOD; PRIORITY JOURNAL; RABBIT; RAT; RESEARCH ETHICS; REVIEW; RISK BENEFIT ANALYSIS; SHEEP; SPINAL MUSCULAR ATROPHY; STEM CELL; TAY SACHS DISEASE; TRANSGENE; TREATMENT OUTCOME; TYROSINEMIA; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; FEMALE; FETAL DISEASES; GENE THERAPY; GENETIC DISEASES, INBORN; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PREGNANCY;

EID: 6344230099     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382828     Document Type: Review

References (133)

1. Editorial. Gene therapy - work in progress. Nat Med 2002; 8: 641.
2. Recombinant DNA Advisory Committee. Recombinant DNA Advisory Committee: minutes of meeting, 1-2 Dec 1994 - Parts VII and XV: ethical considerations relative to in utero somatic cell and gene therapies (discussion and presentation). Hum Gene Ther 1995; 6: 1065, 1077-1065, 1097.
3. Clapp DW, Dumenco LL, Hatzoglou M, Gerson SL. Fetal liver hematopoietic stem cells as a target for in utero retroviral gene transfer. Blood 1991; 78: 1132-1139.
4. Kantoff PW, Flake AW, Eglitis MA, Scharf S, Bond S, Gilboa E, et al. In utero gene transfer and expression: a sheep transplantation model. Blood 1989; 73: 1066-1073.
5. Ekhterae D, Crumbleholme T, Karson E, Harrison MR, Anderson WF, Zanjani ED. Retroviral vector-mediated transfer of the bacteria neomycin resistance gene into fetal and adult sheep and human hematopoietic progenitors in vitro. Blood 1990; 75: 365-369.
6. Zanjani ED, Pallavicini MG, Ascensao JL, Flake AW, Langlois RG, Reitsma M, et al. Engraftment and long-term expression of human fetal hemopoietic stem cells in sheep following transplantation in utero. J Clin Invest 1992; 89: 1178-1188.
7. Crombleholme TM, Bianchi DW. In utero hematopoietic stem cell transplantation and gene therapy. Semin Perinatol 1994; 18: 376-84.
8. Pitt BR, Schwarz MA, Pilewski JM, Nakayama D, Mueller GM, Robbins PD, et al. Retrovirus-mediated gene transfer in lungs of living fetal sheep. Gene Ther 1995; 2: 344-350.
9. Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation. A status report. JAMA 1997; 278: 932-937.
10. Porada CD, Tran N, Eglitis M, Moen RC, Troutman L, Flake AW, et al. In utero gene therapy: transfer and long-term expression of the bacterial neo(r) gene in sheep after direct injection of retroviral vectors into preimmune fetuses. Hum Gene Ther 1998; 9: 1571-1585.
11. Carrier E, Gilpin E, Lee TH, Busch MP, Zanetti M. Microchimerism does not induce tolerance after in utero transplantation and may lead to the development of alloreactivity. J Lab Clin Med 2000; 136: 224-235.
12. Larson JE, Morrow SL, Happel L, Sharp JF, Cohen JC. Reversal of cystic fibrosis phenotype in mice by gene therapy in utero. Lancet 1997; 349: 619-620.
13. Duan D, Sehgal A, Yao J, Engelhardt JF. Left transcription factor expression defines airway progenitor cell targets for in utero gene therapy of submucosal gland in cystic fibrosis. Am J Respir Cell Mol Biol 1998; 18: 750-758.
14. Mason CA, Bigras JL, O'Blenes SB, Zhou B, McIntyre B, Nakamura N, et al. Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectin-dependent neointimal formation. Nat Med 1999; 5: 176-182.
15. Department of Health and Human Services. National Institutes of Health. Recombinant DNA Advisory Committee. Minutes of meeting. March 6-7, 1997. Hum Gene Ther 1997; 8: 1955-2004.
16. Office of Recombinant DNA Activities; recombinant DNA research: action under the guidelines. National Institutes of Health (NIH), PHS, DHHS. Notice of action under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines). Fed Regist 1999; 64: 25361-25362.
17. Abstracts from the 5th Annual Meeting of the American Society of Gene Therapy. June 5-9, 2002. Mol Ther 2002; 5: S1-471.
18. Annas GJ, Elias S. Legal and ethical implications of fetal diagnosis and gene therapy. Am J Med Genet 1990; 35: 215-218.
19. Post SG. Selective abortion and gene therapy: reflections on human limits. Hum Gene Ther 1991; 2: 229-233.
20. Chervenak FA, McCullough LB. Ethical issues in recommending and offering fetal therapy. West J Med 1993; 159: 369-399.
21. Pergament E, Fiddler M. Prenatal gene therapy: prospects and issues. Prenat Diagn 1995; 15: 1303-1311.
22. Fletcher JC, Richter G. Human fetal gene therapy: moral and ethical questions. Hum Gene Ther 1996; 7: 1605-1614.
23. Billings PR. In utero gene therapy: the case against. Nat Med 1999; 5: 255-256.
24. Schneider H, Coutelle C. In utero gene therapy: the case for. Nat Med 1999; 5: 256-257.
25. Glass KC, Weijer C, Cournoyer D, Lemmens T, Palmour RM, Shapiro SH, et al. Structuring the review of human genetics protocols, part III: gene therapy studies. IRB 1999; 21: 1-9.
26. Health Research Extension Act of 1985. Public Law 99-158. US Statut Large 1985; 99.
27. Burger IM, Wilfond BS. Limitations of informed consent for in utero gene transfer research: implications for investigators and institutional review boards. Hum Gene Ther 2000; 11: 1057-1063.
28. Flake AW, Roncarolo MG, Puck JM, Almeida-Porada G, Evans MI, Johnson MP, et al. Treatment of X-Linked Severe Combined Immunodeficiency by in utero Transplantation of Paternal Bone Marrow. N Engl J Med 1996; 335: 1806-1810.
29. Anderson WF. Human gene therapy. Nature 1998; 392: 25-30.
30. Conneally E, Eaves CJ, Humphries RK. Efficient retroviral-mediated gene transfer to human cord blood stem cells with in vivo repopulating potential. Blood 1998; 91: 3487-3493.
31. Frey BM, Hackett NR, Bergelson JM, Finberg R, Crystal RG, Moore MA, et al. High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitors and precursor cells by adenovirus vectors. Blood 1998; 91: 2781-2792.
32. MacKenzie TC, Kobinger GP, Kootstra NA, Radu A, Sena-Esteves M, Bouchard S, et al. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol Ther 2002; 6: 349-358.
33. Iwamoto HS, Trapnell BC, McConnell CJ, Daugherty C, Whitsett JA. Pulmonary inflammation associated with repeated, prenatal exposure to an E1, E3-deleted adenoviral vector in sheep. Gene Ther 1999; 6: 98-106.
34. Yang EY, Cass DL, Sylvester KG, Wilson JM, Adzick NS. BAPS Prize - 1997. Fetal gene therapy: efficacy, toxicity, and immunologic effects of early gestation recombinant adenovirus. British Association of Paediatric Surgeons. J Pediatr Surg 1999; 34: 235-241.
35. Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 1997; 94: 12133-12138.
36. Liu JM, Young NS, Walsh CE, Cottler-Fox M, Carter C, Dunbar C. et al. Retroviral mediated gene transfer of the Fanconi anemia complementation group C gene to hematopoietic progenitors of group C patients. Hum Gene Ther 1997; 8: 1715-1730.
37. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Bercnson R, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048-3057.
38. Hanania EG, Giles R, Kavanagh J, Ellerson D, Zu Z, Wang T, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 1996; 93: 15346-15351.
39. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, et al. Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA- Immunodeficient Patients. Science 1995; 270: 470-475.
40. Dunbar C, Kohn D. Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A phase I study. Hum Gene Ther 1996; 7: 231-253.
41. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995; 1: 1017-1023.
42. Anderson WF. Human gene therapy. Science 1992; 256: 808-813.
43. Letourneau P, Niyonsenga T, Carrier E, Praud E, Praud JP. Influence of 24-hour sleep deprivation on respiration in lambs. Pediatr Res 2002; 52: 697-705.
44. Sefrioui H, Donahue J, Srivastava AS, Gilpin E, Lee TH, Carrier E. Alloreactivity following in utero transplantation of cytokine-stimulated hematopoietic stem cells: the role of recipient CD4(-) cells. Exp Hematol 2002; 30: 617-24.
45. Billingham R, Brent L, Medawar PB. Quanitative studies on tissue transplantation immunity. Philos Trans R Soc Lond Ser B Biol Sci 1956; 239: 357.
46. Binns RM. Bone marrow and lymphoid cell injection of the pig foetus resulting in transplantation tolerance or immunity, and immunoglobulin production. Nature 1967; 214: 179-180.
47. Zanjani ED, Flake AW, Rice H, Hedrick M, Tavassoli M. Long-term repopulating ability of xenogeneic transplanted human fetal liver hematopoietic stem cells in sheep. J Clin Invest 1994; 93: 1051-1055.
48. Marrack P, Lo D, Brinster R, Palmiter R, Burkly L, Flavell RH, et al. The effect of thymus environment on T cell development and tolerance. Cell 1988; 53: 627-634.
49. Schwartz RH. Acquisition of immunologic self-tolerance. Cell. 1989; 57:1073-81.
50. Mychaliska GB, Rice HE, Tarantal AF, Stock PG, Capper J, Garovoy MR, et al. In utero hematopoietic stem cell transplants prolong survival of postnatal kidney transplantation in monkeys. J Pediatr Surg 1997; 32: 976-981.
51. DeMatteo RP, Raper SE, Ahn M, Fisher KJ, Burke C, Radu A, et al. Gene transfer to the thymus. A means of abrogating the immune response to recombinant adenovirus. Ann Surg 1995; 222: 229-239.
52. Flake AW, Harrison MR, Zanjani ED. In utero stem cell transplantation. Exp Hematol 1991; 19: 1061-1064.
53. Zanjani ED, Ascensao JL, Tavassoli M. Liver-derived fetal hematopoietic stem cells selectively and preferentially home to the fetal bone marrow. Blood 1993; 81: 399-404.
54. Harrison MR, Slotnick RN, Crombleholme TM, Golbus MS, Tarantal AF, Zanjani ED. In utero transplantation of fetal liver haemopoietic stem cells in monkeys. Lancet 1989; 2: 1425-1427.
55. Wengler GS, Lanfranchi A, Frusca T, Verardi R, Neva A, Brugnoni D, et al. In utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI). Lancet 1996; 348: 1484-1487.
56. Westgren M, Ringden O, Eik-Nes S, Ek S, Anvret M, Brubakk AM, et al. Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies. Transplantation 1996; 61: 1176-1179.
57. Owens RD. Immunologenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102: 400-401. WASHINGTON, AMER ASSOC ADVANCEMENT SCIENCE.
58. Jolly RD, Thompson KG, Murphy CE, Manktelow BW, Bruere AN, Winchester BG. Enzyme replacement therapy - an experiment of nature in a chimeric mannosidosis calf. Pediatr Res 1976; 10: 219-224.
59. Fleischman RA, Mintz B. Prevention of genetic anemias in mice by microinjection of normal hematopoietic stem cells into the fetal placenta. Proc Natl Acad Sci USA 1979; 76: 5736-5740.
60. Picus J, Aldrich WR. Letvin NL. A naturally occurring bone-marrow-chimeric primate. I. Integrity of its immune system. Transplantation 1985; 39: 297-303.
61. van Dijk BA, Boomsma DI, de Man AJ. Blood group chimerism in human multiple births is not rare. Am J Med Genet 1996; 61: 264-268.
62. Zanjani ED, MacKintosh FR, Harrison MR. Hematopoietic chimerism in sheep and nonhuman primates by in utero transplantation of fetal hematopoietic stem cells. Blood Cells 1991; 17: 349-363.
63. Tebbutt SJ, Lakeman MB, Wilson-Wheeler JC, Hill DF. Genetic variation within the ovine cystic fibrosis transmembrane conductance regulator gene. Mutat Res 1998; 382: 93-98.
64. Campbell KH, McWhir J, Ritchie WA, Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature 1996; 380: 64-66.
65. Almeida-Porada G, El Shabrawy D, Porada C, Zanjani ED. Differentiative potential of human metanephric mesenchymal cells. Exp Hematol 2002; 30: 1454-1462.
66. Zanjani ED, Anderson WF. Prospects for in utero human gene therapy. Science 1999; 285: 2084-2088.
67. Hayashi SI, Morishita R, Aoki M, Moriguchi A, Kida I, Nakajima M, et al. In vivo transfer of gene and oligodeoxynucleotides into skin of fetal rats by incubation in amniotic fluid. Gene Ther 1996; 3: 878-885.
68. Sekhon HS, Larson JE. In utero gene transfer into the pulmonary epithelium. Nat Med 1995; 1: 1201-1203.
69. Koch KS, Brownlee GG, Goss SJ, Martinez-Conde A, Leffert HL. Retroviral vector infection and transplantation in rats of primary fetal rat hepatocytes. J Cell Sci 1991; 99: 121-130.
70. Woo YJ, Raju GP, Swain JL, Richmond ME, Gardner TJ, Balice-Gordon RJ. In utero cardiac gene transfer via intraplacental delivery of recombinant adenovirus. Circulation 1997; 96: 3561-3569.
71. Holzinger A, Trapnell BC, Weaver TE, Whitsett JA, Iwamoto HS. Intraamniotic administration of an adenoviral vector for gene transfer to fetal sheep and mouse tissues. Pediatr Res 1995; 38: 844-850.
72. Senut MC, Suhr ST, Gage FH. Gene Transfer to the Rodent Placenta In Situ . A New Strategy for Delivering Gene Products to the Fetus. J Clin Invest 1998; 101: 1565-1571.
73. Romano G, Pacilio C, Giordano A. Gene Transfer Technology in Therapy: Current Applications and Future Goals. Stem Cells 1999; 17: 191-202.
74. Weiss RA. Retroviral zoonoses. Nat Med 1998; 4: 391-392.
75. Weiss RA, Wrangham RW. From Pan to pandemic. Nature 1999; 397: 385-386.
76. Shinnick TM, Lerner RA, Sutcliffe JG. Nucleotide sequence of Moloney murine leukaemia virus. Nature 1981; 293: 543-548.
77. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39.
78. Cooper D, Penny R, Symonds G, Carr A, Gerlach W, Sun LQ, et al. A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins. Hum Gene Ther 1999; 10: 1401-1421.
79. Amado RG, Mitsuyasu RT, Symonds G, Rosenblatt JD, Zack J, Sun LQ, et al. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther 1999; 10: 2255-2270.
80. Morgan RA. Gene therapy for HIV infection. Clin Exp Immunol 1997; 107 Suppl 1: 41-44.
81. Podsakoff G, Wong KK Jr, Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 1994; 68: 5656-5666.
82. Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Valdez P, et al. A Clinical Trial of Retroviral-Mediated Transfer of a rev-Responsive Element Decoy Gene Into CD34+ Cells From the Bone Marrow of Human Immunodeficiency Virus-1-Infected Children. Blood 1999; 94: 368-371.
83. Slobod KS, Bennett TA, Freiden PJ. Kechli AM, Howlett N, Flynn PM, et al. Mobilization of CD34+ progenitor cells by granulocyte colony- stimulating factor in human immunodeficiency virus type 1-infected adults. Blood 1996; 88: 3329-3335.
84. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector. Science 1996; 272: 263-267.
85. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
86. Poeschla E, Corbeau P, Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 1996; 93: 11395-11399.
87. Srinivasakumar N, Chazal N, Helga-Maria C, Prasad S, Hammarskjold ML, Rekosh D. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol 1997; 71: 5841-5848.
88. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
89. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1. J Virol 1998; 72: 811-816.
90. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of Human CD34+ Cells That Mediate Long-Term Engraftment of NOD/SCID Mice by HIV Vectors. Science 1999; 283: 682-686.
91. Johnston JC, Gasmi M, Lim LE, Elder JH, Yee JK, Jolly DJ, et al. Minimum Requirements for Efficient Transduction of Dividing and Nondividing Cells by Feline Immunodeficiency Virus Vectors. J Virol 1999; 73: 4991-5000.
92. Johnston J, Power C. Productive Infection of Human Peripheral Blood Mononuclear Cells by Feline Immunodeficiency Virus: Implications for Vector Development. J Virol 1999; 73: 2491-2498.
93. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4: 354-357.
94. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-4242.
95. Russell DW, Miller AD. Foamy virus vectors. J Virol 1996; 70: 217-222.
96. Wu M, Mergia A. Packaging Cell Lines for Simian Foamy Virus Type 1 Vectors. J Virol 1999; 73: 4498-4501.
97. Wu M, Chari S, Yanchis T, Mergia A. cis-Acting Sequences Required for Simian Foamy Virus Type I Vectors. J Virol 1998; 72: 3451-3454.
98. Bieniasz PD, Weiss RA, McClure MO. Cell cycle dependence of foamy retrovirus infection. J Virol 1995; 69: 7295-7299.
99. Ferry N, Heard JM. Liver-directed gene transfer vectors. Hum Gene Ther 1998; 9: 1975-1981.
100. Nyberg-Hoffman C, Aguilar-Cordova E. Instability of adenoviral vectors during transport and its implication for clinical studies. Nat Med 1999; 5: 955-957.
101. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75: 207-216.
102. Batshaw ML, Wilson JM, Raper S, Yudkoff M, Robinson MB. Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). Hum Gene Ther 1999; 10: 2419-2437.
103. Blacklow NR, Hoggan MD, Kapikian AZ, Austin JB, Rowe WP. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 1968; 88: 368-378.
104. Berns KI, Pinkerton TC, Thomas GF, Hoggan MD. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 1975; 68: 556-560.
105. Russell DW, Miller AD, Alexander IE. Adeno-Associated Virus Vectors Preferentially Transduce Cells in S Phase. Proc Natl Acad Sci USA 1994; 91: 8915-8919.
106. Lebkowski JS, McNally MM, Okarma TB, Lerch LB. Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types. Mol Cell Biol 1988; 8: 3988-3996.
107. Cheung AK, Hoggan MD, Hauswirth WW, Berns KI. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol 1980; 33: 739-748.
108. Kotin RM, Berns KI. Organization of adeno-associated virus DNA in latently infected Detroit 6 cells. Virology 1989; 170: 460-467.
109. Kotin RM, Siniscalco M, Samulski RJ, Zhu X, Hunter L, Laughlin CA, et al. Site-Specific Integration by Adeno-Associated Virus. Proc Nat Acad Sci USA 1990; 87: 2211-2215.
110. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992; 11: 5071-5078.
111. Kotin RM, Menninger JC, Ward DC, Berns KI. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991; 10: 831-834.
112. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19 published erratum appears in EMBO J 1992 Mar; 11(3): 1228]. EMBO J 1991; 10: 3941-3950.
113. Buller RM, Janik JE, Sebring ED, Rose JA. Herpes simplex virus types 1 and 2 completely help adenovirus- associated virus replication. J Virol 1981; 40: 241-247.
114. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci USA 1966; 55: 1467-1474.
115. Weindler FW, Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol 1991; 65: 2476-2483.
116. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82.
117. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999; 5: 71-77.
118. Summerford C, Samulski RJ. Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions. J Virol 1998; 72: 1438-1445.
119. Ponnazhagan S, Mukherjee P, Wang XS, Qing K, Kube DM, Mah C, et al. Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. J Virol 1997; 71: 8262-8267.
120. Martineau D, Klump WM, McCormack .JE, DePolo NJ, Kamantigue E, Petrowski M, et al. Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus. Hum Gene Ther 1997; 8: 1231-1241.
121. Nemunaitis J, Fong T, Burrows F, Bruce J, Peters G, Ognoskie N, et al. Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma. Hum Gene Ther 1999; 10: 1289-1298.
122. Santti J, Hyypia T, Kinnunen L, Salminen M. Evidence of Recombination among Enteroviruses. J Virol 1999; 73: 8741-8749.
123. Johnson WE, Coffin JM. Constructing primate phylogenies from ancient retrovirus sequences. Proc Nat Acad Sci USA 1999; 96: 10254-10260.
124. Larsson E, Andersson G. Beneficial role of human endogenous retroviruses: facts and hypotheses. Scand J Immunol 1998; 48: 329-338.
125. Lower R, Boller K, Hasenmaier B, Korbmacher C, Muller-Lantzsch N, Lower J, et al. Identification of Human Endogenous Retroviruses with Complex mRNA Expression and Particle Formation. Proc Natl Acad Sci USA 1993; 90: 4480-4484.
126. Zhao Y, Zhu L, Lee S, Li L, Chang E, Soong NW, et al. Identification of the block in targeted retroviral-mediated gene transfer. Proc Natl Acad Sci USA 1999; 96: 4005-4010.
127. Ye X, Gao GP, Pabin C, Raper SE, Wilson JM. Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum Gene Ther 1998; 9: 2135-2142.
128. Zhu J, Grace M, Casale J, Chang AT, Musco ML, Bordens R, et al. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector. Hum Gene Ther 1999; 10: 113-121.
129. Report of the Committee on the Ethics of Gene Therapy. Hum Gene Ther 1992; 3: 519-523.
130. Caplan AL, Wilson JM. The ethical challenges of in utero gene therapy. Nat Genet 2000; 24: 107.
131. Furlan R, Pluchino S, Martino G. Gene therapy-mediated modulation of immune processes in the central nervous system. Curr Pharm Design 2003; 9(24): 2002-8.
132. Tomita N, Morishita R. Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases. Curr Pharm Design 2004; 10(7): 797-803.
133. Vogt PH. Molecular genetics of human male infertility: from genes to new therapeutic perspectives. Curr Pharm Design 2004; 10(5): 471-500.